[235]
This is inconsistent with Justice Hughes' own finding in paragraph 67 of the Reasons that "shortly after Daiichi had filed its Japanese patent applications at least four competitor groups announced that they had used identical methods to derive the same enantiomer". (Novopharm Notice of Appeal.)
(c) The properties of levofloxacin were not expected